Search Results

You are looking at 1 - 10 of 105 items for :

  • "bladder cancer" x
Clear All
Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer and Maria Ho

estimated 73,510 new cases of urinary bladder cancer will be diagnosed in the United States (55,600 men and 17,910 women) in 2012. 1 Bladder cancer, the fourth most common cancer, is 3 times more common in men than in women in the United States. During the

Full access

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer and Lisa A. Gurski

estimated 79,030 new cases of urinary bladder cancer (60,490 men and 18,540 women) will be diagnosed in the United States in 2017 and approximately 16,870 deaths (12,240 men and 4630 women) will occur. 1 Bladder cancer, the sixth most common cancer in the

Full access

Sumanta K. Pal, Matthew I. Milowsky and Elizabeth R. Plimack

agents have been approved for metastatic castration-resistant prostate cancer (mCRPC) since 2009. 2 This rapid progress has not been observed in bladder cancer. Cisplatin, which remains the cornerstone of systemic therapy for the disease, was first noted

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng and Christopher M. Booth

Background With approximately 75,000 new diagnoses and 15,000 deaths each year in the United States, bladder cancer is the sixth most common cancer and eighth leading cause of cancer death. Approximately 30% of patients with bladder cancer

Full access

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther and Timothy G. Wilson

the express written permission of the NCCN © 2009. Disclosures for the NCCN Bladder Cancer Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

Full access

Jeffrey S. Montgomery, David C. Miller and Alon Z. Weizer

-invasive bladder cancer. Discuss treatment recommendations and guidelines for non–muscle-invasive and muscle-invasive bladder cancer. Driven by third-party payers, patients, and health care providers, increasing interest has been shown in improving

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou and Anthony L. Zietman

Bladder cancer is the sixth most common cancer in the United States, with approximately 73,510 patients diagnosed and 14,800 dying of the disease in 2012. 1 When the cancer invades into or beyond the muscularis propria (muscle-invasive bladder

Full access

Thomas W. Flaig

“There has been no major change in the incidence of bladder cancer in the United States for 40 years, and for 30 years there has been almost no therapeutic development for localized or advanced disease. However, in the past few years, 5 immune

Full access

S. Machele Donat

Cancer J Clin 2008 : 58 : 71 – 96 . 2 Stein JP Lieskovsky G Cote R . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients . J Clin Oncol 2001 ; 19 : 666 – 675 . 3 Dalbagni G Genega

Full access

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer and Lisa A. Gurski

: September 10, 2018; Expiration date: September 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Bladder Cancer Describe the rationale